Glenmark Pharma US Arm Launches Epinephrine Injection

Glenmark Pharmaceuticals, US subsidiary, Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, the company said in a notification to exchanges.

Glenmark stated that its Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) manufactured by BPI Labs, LLC.

According to sales data from IQVIA for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market achieved annual sales of approximately $67.6 million. This figure includes the brand and all available therapeutic equivalents, as reported in IQVIA National Sales Perspectives: Retail & Non-Retail.

Marc Kikuchi, President & Business Head, North America, said: “We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”